VTAK
Get informed when a big investor buys or sells
+ FollowOvervalued by 113.8% based on the discounted cash flow analysis.
| Market cap | $950,817.00 |
|---|---|
| Enterprise Value | $12.63 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-15.9 |
| Beta | 0.32 |
| Outstanding Shares | 2,191,831,000 |
| P/E Ratio | -130.16 |
|---|---|
| PEG | 524.39 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.69 |
| Enterprise Value to EBIT | -0.56 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.96 |
| Debt to Equity | 1.27 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.00% |
|---|---|
| Total Invested | $102,926▼ 17.76% |
| Investors Holding | 12▲ 3.00% |
No data
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we...